Free Trial
NASDAQ:IMCC

IM Cannabis Q2 2025 Earnings Report

IM Cannabis logo
$2.62 +0.06 (+2.14%)
As of 03:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IM Cannabis EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

IM Cannabis Revenue Results

Actual Revenue
$9.21 million
Expected Revenue
$12.88 million
Beat/Miss
Missed by -$3.67 million
YoY Revenue Growth
N/A

IM Cannabis Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
9:00AM ET

Earnings Documents

IM Cannabis Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
IM Cannabis Reports Second Quarter 2025 Financial Results
See More IM Cannabis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IM Cannabis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IM Cannabis and other key companies, straight to your email.

About IM Cannabis

IM Cannabis (NASDAQ:IMCC) engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

View IM Cannabis Profile

More Earnings Resources from MarketBeat